title: [The doxazosin treatment of the changes in the bladder filling phase in benign prostatic hyperplasia].
abstract: OBJECTIVE
  To analyze the clinical and urodynamic efficacy of treatment with doxazosin during 6 months for bladder filling phase disorders in patients with BPH.
  
  
  METHODS
  A prospective clinical and urodynamic study was performed in 65 males with BPH, aged 54-79 years (mean 66.7), who had been treated with doxazosin (4 mg/day) during 6 months. Clinical [International Prostatic Symptom Score (IPSS)] and urodynamic evaluations (cystometry and filling cystography) before and after treatment were performed. IPSS data were obtained according to the WHO recommendation following validation and translation into Spanish.
  
  
  RESULTS
  The IPSS score improved significantly from 19.8 +/- 4.8 before treatment to 11.9 +/- 4.6 after treatment (p < 0.001). All the patients were normotensive before and after treatment (systolic and diastolic blood pressures 135.9/78.9 and 135.4/77.8 mmHg, respectively). No tachycardia was observed before (71.9 +/- 5.8) or after treatment (71.8 +/- 5.9). A relationship between the lower IPSS before treatment and urinary symptoms improvement was demonstrated (coef.-0.45939). We found no relationship between prostate volume (digital rectal examination or transabdominal ultrasonography) and IPSS modifications after treatment. Bladder instability decreased significantly from 71.6% before treatment to 33.3% after treatment (p < 0.01). Instability pressure also diminished from 99.2 cms H2O to 60.3 cms H2O after doxazosin treatment (p < 0.001). We found no significant relationship between IPSS and bladder instability post-treatment.
  
  
  CONCLUSIONS
  Adrenergic blockade with doxazosin 4 mg/day for 6 months achieves a significant decrease in the bladder instability associated with prostatic obstruction in patients with BPH, although no statistical correlation with the IPSS could be demonstrated.
authors.affiliation: Servicio de Urología, Hospital Clínico Universitario San Carlos, Universidad Complutense, Madrid.
authors.forename: J
authors.initials: J
authors.lastname: Salinas Casado
authors.forename: M
authors.initials: M
authors.lastname: Esteban Fuertes
authors.forename: M
authors.initials: M
authors.lastname: Virseda Chamorro
authors.forename: J C
authors.initials: JC
authors.lastname: Ramírez Fernández
authors.forename: S
authors.initials: S
authors.lastname: Salomón Moh'd
authors.forename: S
authors.initials: S
authors.lastname: Luengo Alpuente
authors.forename: L
authors.initials: L
authors.lastname: Resel Estévez
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000368:Aged; D017292:Doxazosin / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D013997:Time Factors; D001743:Urinary Bladder / Q000187:drug effects* / Q000503:physiopathology; D014563:Urodynamics / Q000187:drug effects
chemical_list: D000317:Adrenergic alpha-Antagonists; D017292:Doxazosin
vernacular_title: Tratamiento con doxazosina de las alteraciones de la fase de llenado vesical en la hiperplasia prostática benigna.